Interplay between whole-genome doubling and the accumulation of deleterious alterations in cancer evolution

Published: 2020-03-05

Affiliations: 52

Authors: 268

Institutions	Authors	Share
UCL Cancer Institute, United Kingdom (UK)		0.16
University College London Hospitals NHS Foundation Trust (UCLH), United Kingdom (UK)		0.10
The Francis Crick Institute, United Kingdom (UK)		0.09
Manchester University NHS Foundation Trust (MFT), United Kingdom (UK)		0.07
Royal Brompton and Harefield NHS Foundation Trust, United Kingdom (UK)		0.07
Sheffield Teaching Hospitals NHS Foundation Trust, United Kingdom (UK)		0.05
University Hospitals Birmingham NHS Foundation Trust (UHB), United Kingdom (UK)		0.04
Aberdeen Royal Infirmary, NHS Grampian, United Kingdom (UK)		0.03
Cancer Research UK and UCL Cancer Trials Centre (UCL CTC), United Kingdom (UK)		0.03
University Hospitals of Leicester NHS Trust (UHL), United Kingdom (UK)		0.03
The Christie NHS Foundation Trust, United Kingdom (UK)		0.03
Leicester Cancer Research Centre (LCRC), United Kingdom (UK)		0.02
Cancer Research UK Manchester Institute, UoM, United Kingdom (UK)		0.02
Cardiff & Vale University Health Board, United Kingdom (UK)		0.02
Manchester Cancer Research Centre (MCRC), United Kingdom (UK)		0.02
Barts Health NHS Trust, United Kingdom (UK)		0.02
University Hospital Southampton NHS Foundation Trust, United Kingdom (UK)		0.02
Golden Jubilee National Hospital, NHSGGC, United Kingdom (UK)		0.02
Liverpool Heart and Chest Hospital, United Kingdom (UK)		0.01
Princess Alexandra Hospital NHS Trust, United Kingdom (UK)		0.01
CRUK Lung Cancer Centre of Excellence, United Kingdom (UK)		0.01
NHS Greater Glasgow and Clyde (NHSGGC), United Kingdom (UK)		0.01
Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, United Kingdom (UK)		0.01
Independent Cancer Patients' Voice (ICPV), United Kingdom (UK)		0.01
Department of Physics of Complex Systems, ELTE, Hungary		0.01
University of Leicester, United Kingdom (UK)		0.01
Ashford and St Peter's Hospitals NHS Foundation Trust, United Kingdom (UK)		0.01
NIHR Leicester Respiratory Biomedical Research Unit (BRU), United Kingdom (UK)		0.01
The Whittington Hospital, Whittington Health NHS, United Kingdom (UK)		0.01
Barnet Hospital, Royal Free London NHS Foundation Trust, United Kingdom (UK)		0.01
Cancer Genomics Laboratory, The Francis Crick Institute, United Kingdom (UK)		0.01
Bioinformatics and Biostatistics Platform, The Francis Crick Institute, United Kingdom (UK)		0
Laboratory for Cell Biology and Genetics, The Rockefeller University, United States of America (USA)		0
Danish Cancer Society Research Center (DCRC), Denmark		0
Velindre Cancer Centre, Velindre NHS Trust, United Kingdom (UK)		0
University College Hospital (UCH), United Kingdom (UK)		0
Ziekenhuis Netwerk Antwerpen (ZNA), Belgium		0
GasthuisZusters Antwerpen (GZA), Belgium		0
Department of Human Genetics, KU Leuven, Belgium		0
DKTK Partner Site Berlin, Germany		0
German Cancer Research Center in the Helmholtz Association (DKFZ), Germany		0
Berlin Institute for Medical Systems Biology (BIMSB), MDC, Germany		0
Department of Molecular Medicine (MOMA), AU, Denmark		0
Brigham and Women's Hospital (BWH), United States of America (USA)		0
Department of Imaging, DFCI, United States of America (USA)		0
Department of Radiation Oncology, DFCI, United States of America (USA)		0
Department of Radiology, NKI, Netherlands		0

Return

Latest supplement

Nature Index 2020 South Korea

A concerted government push to make South Korea an innovation leader, backed by strong investment and systemic reform, has brought rapid and long-lasting results. The country’s scientific landscape is becoming more diverse and more productive, as a place where upwardly mobile researchers thrive.

Access free